<?xml version="1.0" encoding="UTF-8"?>

<!--L
  Copyright Oracle Inc

  Distributed under the OSI-approved BSD 3-Clause License.
  See http://ncip.github.com/cadsr-cgmdr-nci-uk/LICENSE.txt for details.
L-->

<cgMDR:Data_Element xmlns:cgMDR="http://www.cancergrid.org/schema/cgMDR" item_registration_authority_identifier="US-NCICB-CACORE" data_identifier="2005642" version="4">
    <cgMDR:administered_item_administration_record>
        <cgMDR:administrative_status>noPendingChanges</cgMDR:administrative_status>
        <cgMDR:creation_date>2007-04-17</cgMDR:creation_date>
        <cgMDR:effective_date>2007-04-17</cgMDR:effective_date>
        <cgMDR:explanatory_comment>Transformed from NCICB caDSR</cgMDR:explanatory_comment>
        <cgMDR:last_change_date>2007-04-17</cgMDR:last_change_date>
        <cgMDR:registration_status>Qualified</cgMDR:registration_status>
    </cgMDR:administered_item_administration_record>
    <cgMDR:administered_by>US-NCICB-CTEP-STEWARD</cgMDR:administered_by>
    <cgMDR:registered_by>US-NCICB-CACORE-REGISTRAR</cgMDR:registered_by>
    <cgMDR:submitted_by>US-NCICB-CTEP-SUMBMITTER</cgMDR:submitted_by>
    <cgMDR:described_by>US-NCICB-CACORE-D1E126089-1</cgMDR:described_by>
    <cgMDR:described_by>US-NCICB-CACORE-D1E126111-1</cgMDR:described_by>
    <cgMDR:described_by>US-NCICB-CACORE-D1E126133-1</cgMDR:described_by>
    <cgMDR:described_by>US-NCICB-CACORE-D1E126156-1</cgMDR:described_by>
    <cgMDR:classified_by/>
    <cgMDR:having>
        <cgMDR:context_identifier>US-NCICB-CTEP-2.31</cgMDR:context_identifier>
        <cgMDR:containing>
            <cgMDR:language_section_language_identifier>
                <cgMDR:country_identifier>US</cgMDR:country_identifier>
                <cgMDR:language_identifier>eng</cgMDR:language_identifier>
            </cgMDR:language_section_language_identifier>
            <cgMDR:name>Common Toxicity Criteria Adverse Event Dysarthria Grade</cgMDR:name>
            <cgMDR:definition_text>in CTC category Pulmonary/Upper Respiratory, assessment of the severity of a voice change or dysarthria (e.g., hoarseness, loss or alteration of voice, laryngitis) adverse event using a graded scale.</cgMDR:definition_text>
            <cgMDR:preferred_designation>true</cgMDR:preferred_designation>
            <cgMDR:definition_source_reference/>
        </cgMDR:containing>
        <cgMDR:containing>
            <cgMDR:language_section_language_identifier>
                <cgMDR:country_identifier>US</cgMDR:country_identifier>
                <cgMDR:language_identifier>eng</cgMDR:language_identifier>
            </cgMDR:language_section_language_identifier>
            <cgMDR:name>CTC_AE_DYSARTHRIA_GD</cgMDR:name>
            <cgMDR:definition_text/>
            <cgMDR:preferred_designation>false</cgMDR:preferred_designation>
            <cgMDR:definition_source_reference/>
        </cgMDR:containing>
    </cgMDR:having>
    <cgMDR:data_element_precision>0</cgMDR:data_element_precision>
    <cgMDR:representation_class_qualifier/>
    <cgMDR:representing>US-NCICB-CACORE-2017841-3</cgMDR:representing>
    <cgMDR:typed_by>GB-CANCERGRID-000018-1</cgMDR:typed_by>
    <cgMDR:expressing>US-NCICB-CACORE-2193384-1</cgMDR:expressing>
    <cgMDR:field_name preferred=""/>
    <cgMDR:question_text preferred=""/>
</cgMDR:Data_Element>